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The leukemia-associated cell surface antigen p 24 is found on normal platelets as well as on Bernard Soulier 
syndrome and thrombasthenia type I platelets. AI& IgG (a monoclonal antibody against p 24) induces 
the aggregation of platelets from normal donors but not from thrombasthenia. In contrast, AI& Fab 
inhibits platelet aggregation i duced by collagen, ADP, thrombin, ionophore A 23187 and ALBe IgG. The 
results uggest that AL&, interferes with a mechanism common to all aggregation pathways; the possible 
mechanisms are discussed. 
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1. INTRODUCTION 
A set of monoclonal antibodies against common 
acute lymphoblastic leukemia has been produced 
in our laboratory [1,2]. Among these antibodies 
one of them, called ALBa, showed a pattern of 
reactivity against various tissues similar to 
monoclonal antibody Baz in [3,4]. These reagents 
react with surface components of many 
hematopoietic and non-hematopoietic cells as 
shown by immunofluorescence studies. These cells 
are either malignant or normal and include a large 
percentage of acute lymphoblastic leukemia and 
neuroblastoma or retinoblastoma cell lines; 
chronic lymphocytic leukemia and acute myeloi’d 
leukemia cells are also slightly labelled in some 
cases. On frozen sections these antibodies have 
been shown to react with distal tubules of the 
kidney and the wall of lymph node vessels 
Biochemical studies have shown that in leukemic 
cells a membrane protein of Mr 24000 (p 24) is im 
munoprecipitated by Baz [3] and ALBs (ir 
preparation). Interestingly these antibodies alsc 
react with a platelet surface component. WC 
therefore studied the effect of ALB6 IgG and ALB, 
Fab on platelet functions and determined the Mr 
value of the platelet molecule identified by ALB6 
2. MATERIALS AND METHODS 
2.1. Antibody production and purification 
Abbreviation: SDS-PAGE; Sodium dodecyl sulfate 
polyacrylamide gel electrophoresis 
.‘*tblished by Elsevier Science Publishers B. V. 
Techniques used for the production 01 
monoclonal antibodies have been reported. ALB( 
is an IgGl which has been produced by fusing 
spleen cells of Balb/c mice, immunized with non-T 
non-B acute lymphoblastic leukemic cells, with 
NSr myeloma cells [ 1,2]. Here, we used either cell 
culture supernatants, ascitic fluids previously 
‘145793/83/$3.00 0 1983 Federation of European Biochemical Societies 28s 
Volume 161, number 2 FEBS LETTERS September 1983 
heated at 55°C for 30 min, or purified antibody 
fractions. Controls were performed using ALBi- 
(anti-common acute lymphoblastic leukemia an- 
tigen) and B4 Fz (anti-HLA monomorphic 
determinant). 
IgG was purified from ascitic fluid by precipita- 
tion in 40% ammonium sulfate. The precipitate 
was dissolved in phosphate buffer (pH 8, 10 mM) 
and desalted on a GFOS column (Industrie Biologi- 
que Francaise) followed by ion-exchange chroma- 
tography on DEAE-trisacryl (IBF) equilibrated in 
phosphate buffer (pH 8, 10 mM). Elution pattern 
with a molarity gradient (O-O.3 M NaCl) showed 
3 major peaks. All the immunological activity was 
found in the first peak. This final preparation con- 
tained 96% globulins and 3% albumin as assessed 
by cellulose acetate electrophoresis. 
After reprecipitation with ammonium sulfate 
ALB6 IgG were dissolved and dialysed against 0.1 
M phosphate buffer (pH 7) containing 10 mM cys- 
teine and 2 mM EDTA to determine the optimal 
conditions for Fab obtention, a cleavage kinetic 
with mercuripapain (Sigma, St Louis MO) at a 2% 
ratio of papain/protein was performed. The reac- 
tion was stopped in an ice bath with 5% 1 M iodo- 
acetic acid (Sigma) in 0.05 M Tris (pH 8). The frac- 
tions were immediately tested by im- 
munofluorescence on platelets and SDS-PAGE 
for assessment of activity and degradation ratio. 
At 6 h the degradation was partial (60%) but the 
preservation of activity was satisfactory. 
Therefore, 3 mg ALB6 were cleaved in these con- 
ditions and undigested IgG was immediately 
separated by Sephadex G-75 gel filtration. Tris, 10 
mM @H 8) was used for elution and the second 
peak containing a mixture of Fc and Fab 
fragments was applied to an ion-exchange DE-52 
(Pharmacia Uppsala) column equilibrated in 10 
mM Tris (pH 8). Fab fragments were easily releas- 
ed by a NaCl gradient (15-50 mM). The solution 
of Fab fragments at 0.4 mg/ml was adjusted to 
0.15 M (pH 7.4) with phosphate buffer. 
2.2. Preparation of platelets and platelet 
aggregation 
2.2.1. Preparation of platelet-rich plasma (PRP) 
Blood was collected into l/9 vol. of 0.13 M 
sodium citrate. PRP was obtained by centrifuga- 
tion at 18°C at 120 x g for 10 min. 
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2.2.2. Preparation of washed platelets 
Venous blood from healthy volunteers and pa- 
tients was anticoagulated with ACD [O.SCro (w/v) 
citric acid, 2.2% (w/v) trisodium citrate, 2.25010 
(w/v) dextrose] at a 4: 5 ratio of blood/anti- 
coagulant. Immediately prior to blood collection, 
apyrase (grade 1, Sigma) and PGEr (Sigma) were 
added to the anticoagulant o a final concentration 
of 25 ng/ml and 20 nM, respectively. PRP was ob- 
tained by centrifugation at 120 xg for 10 min at 
18°C and then the PRP was recentrifuged at 
1200 x g for 10 min. The pellet was resuspended in 
washing buffer (36 mM citric acid, 5 mM glucose, 
5 mM KCI, 2 mM CaCl2, 1 mM MgCl2, 103 mM 
NaCl, 20 mM PEGr, 25 ng apyrase/ml and 3.5 mg 
BSA/ml, adjusted to pH 6.5). After two washings 
carried out in plastic tubes at room temperature, 
the platelets were resuspended in tyrode buffer @H 
7.35, 137 mM NaCl, 2 mM KCI, 12 mM NaHCOs, 
0.3 mM POdHzNa, 2.9 mM CaCl2, 1 mM MgCl2, 
5.5 mM glucose and 3.5 mg BSA/ml). 
2.2.3. Preparation of fixed platelets 
Washed platelets were resuspended in tyrode 
buffer without albumin in the presence of 1% for- 
maldehyde for 18 h at room temperature. After 5 
washings, the platelets were resuspended in tyrode 
buffer without BSA. 
2.2.4. Platelet aggregation 
Platelet aggregation was measured as in [5]. 
Platelet aggregation was followed by recording 
light transmission through a stirred platelet 
suspension (3 X lOs/ml) in an aggregometer cuvette 
(Chronolog Coultronic) at 37°C in a final volume 
of 0.4 ml. 
The apparatus was calibrated so that platelet 
suspension (or PRP) and buffer solution (or PPP) 
produced 90 and 0 absorbance units (AU), respec- 
tively. Lag phase before platelet aggregation was 
measured and the extent of platelet aggregation 
was evaluated when aggregation was complete and 
expressed in AU. ADP, collagen, (from bovine 
achille tendon, dissolved in glycine buffer, pH 4), 
arachidonic acid, thrombin, ionophore A23187 
and ristocetin were used as aggregating agents (the 
concentration was noted for each result). The 
absence of lysis was assessed by assaying lactate 
dehydrogenase in the supernatant (LDH optimized 
UV test, Merck, Darmstadt). 
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2.2.5. ALBa IgG-induced platelet aggregation 
Various amounts of culture supernatants, ascitic 
fluid or purified IgG were tested both on PRP and 
washed platelets from normal donors and from 
thrombasthenia nd Bernard Soulier syndrome pa- 
tients. ALBe Fab was also tested. 
2.2.6. Inhibition of ALB,s platelet aggregation 
Various amounts of EDTA, PGE, aspirin (lysine 
salt), ticlopidin, chlorpromazin and diltiazem 
diluted in 0.15 M NaCl were added to 0.3 ml 
platelet suspensions, before adding 0.1 ml ALBa 
IgG and aggregation was measured. The same 
amount of solvent was used as control. 
2.2.7. Effect of ALB6 Fab fragments on platelet 
aggregation induced by aggregating agent 
ALBs Fab fragments (0.1 ml 4OOpg/ml) were in- 
cubated with either 0.3 ml PRP (0.3 ml washed 
platelets) for 4 min at 37°C with continuous stir- 
ring (in the aggregometer). Then, the aggregating 
agent was added and the aggregation curves were 
recorded. Controls with buffer alone were always 
performed. 
2.3. Immunofluorescence 
Washed platelets were used for immunofluores- 
cence. Samples of 3 x lo6 platelets in 20 pl Tyrode 
buffer were incubated at 4°C for 30 min with ap- 
propriate dilutions of ALBe, washed 3-times and 
incubated with FITC-labelled goat antimouse Ig. 
Examination of the preparation was performed on 
a Zeiss 2 microscope equipped with epifluores- 
cence. Controls were performed using other 
monoclonal antibodies B4 FZ and ALBr . 
2.4. Effect of ALB6 Fab on fibrinogen-binding 
to platelets 
Binding of [1251]fibrinogen to ADP-treated 
platelets was performed as in [6]. The binding was 
measured on platelets in the presence or absence of 
ALBs Fab (10 min incubation with 6Opg/ml ALB6 
Fab) before ADP addition. The results were ex- 
pressed in percentages of fibrinogen bound to 
platelets. 
2.5. Molecular mass determination of the antigen 
recognized by ALBa ‘251-Iabelling of platelets 
Platelets (3 x 108) in 100 ml Tyrode buffer were 
labelled with 400 &i 12’1 by the addition of 1OOpg 
chloramine T. The reaction was stopped after 1 
min incubation by dilution and rapid washing in 
ice-cold Tyrode’s buffer. The cells were lysed by 
resuspension in ice-cold extraction buffer NET NP 
40 (NaCl30 mM, Tris 30 mM, EDTA 1 mM, NP 
40 1%) PMSF 2 mM). The extract was centrifuged 
at 1000 xg for 10 min and the supernatants ali- 
quoted and kept at - 70°C. 
2.6. Immunoadsorption and SDS-PAGE 
After ultracentrifugation for 10 min in an air- 
fuge (Beckman) to eliminate residual cell mem- 
branes, the extracts were passed through 
microcolumns (5 ~1) of immunoadsorbents 
(glutaraldehyde-activated ultrogels coated with 
ALBi IgG, ALB6 IgG or non-specific mouse IgG) 
as in [7]. After washing, the immunoadsorb,ent was 
directly plunged into 50~10.0625 M Tris-HCl buf- 
fer (pH 6.8) containing 5% (v/v) 2 mercapto- 
ethanol, 10% (v/v) glycerol, 2% SDS and 0.001% 
(w/v) bromophenol blue. After dissociation for 2 
min in boiling water, the samples were analyzed by 
SDS-PAGE gradient gel electrophoresis as in [8] 
except that the running gel was 5-20% (w/v) 
acrylamide. After drying of the gels, labelled pro- 
teins were detected by autoradiography. 
3. RESULTS 
3.1. Induction of platelet aggregation by ALBa 
As shown in fig. 1 addition of ALB6 IgG to PRP 
led to a typical aggregation pattern preceded by a 
lag phase. (Just before aggregation a slight in- 
crease in absorbance was seen.) The same was 
observed with washed platelets without addition of 
fibrinogen (not shown). This aggregation could be 
obtained with heated supematants or ascites as 
well as with purified IgG. The lag phase increased 
with increasing dilutions of ALBa IgG (fig. 1). 
However, the intensity of maximal aggregation 
was independent of the quantity of ALBa IgG. Bet- 
ween 2-32 pg/ml there is a linear relationship bet- 
ween the inverse of the concentration of ALBa IgG 
and the logarithm of the lag phase (not shown). 
The minimal concentration after 30 min was 
observed at 1 g/ml. None of the monoclonal anti- 
bodies used as controls ALBl or B4 FZ induced ag- 
gregation. In order to eliminate the action of pro- 
teolytic enzymes contained in supernatants or 
291 
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Fig. 1. Platelet aggregation induced by ALBa IgG. There 
is an increase in the lag phase with decreasing concentra- 
tions of AI& IgG without a change in the intensity of 
maximal aggregation. The lag phase observed at 64 and 
128pg/ml was identical to 32pg/ml (O.D.U. absorbance 
units). 
ascitic fluids we checked that neither iniprol (lo3 
units/ml) nor heparin antithrombin III (to inhibit 
thrombin) inhibited ALB6 IgG-induced platelet ag- 
gregation. ALB6 IgG induced to the same extent 
platelet aggregation from normal PRP and from 
PRP of Bernard Soulier syndrome. No aggrega- 
tion however occurred when ALB6 was added to 
PRP of a thrombasthenia type I and 2 throm- 
basthenia type II patients, only a change in shape 
was observed. ALB6 IgG even at high concentra- 
tions did not induce agglutination of formalde- 
hyde-fixed platelets. The level of LDH in PRP was 
not increased after ALBe-induced platelet 
aggregation. 
3.2. Effect of ALB6 Fab fragments 
No aggregation was observed with purified 
ALB6 Fab fragments up to 100 g/ml. Conversely 
Fab fragments inhibited AI&-induced platelet ag- 
gregation. When Fab fragments and purified IgG 
(used at 100 pg/ml and 4 rg/ml, respectively) were 
added simultaneously in PRP 50% inhibition of 
ALBe-induced aggregation was observed (velocity 
and maximal intensity). When ALB6 Fab was pre- 
incubated with the PRP (5 min at 37°C with stir- 
ring) the inhibition was total. In these conditions 
100 pg/ml and 75 pg/ml ALB6 Fab completely in- 
hibited ALB6 IgG platelet aggregation whereas 
50gg/ml ALB6 Fab led to slightly delayed 
aggregation. 
Preincubation for 5 min of PRP with ALB6 Fab 
(at lOOpg/ml) totally inhibited platelet aggregation 
induced by collagen (0.4 as/ml), arachidonic acid 
(0.6 ,uM), ADP (2.5 PM) and on washed platelets 
by thrombin (0.1 units/ml). ALB6 Fab also in- 
hibited aggregation by ionophore A 23187 but this 
effect was with low doses (7.5,uM) as ionophore in- 
duces only partial aggregation. At higher doses (15 
,uM) Fab fragments partially inhibited the aggrega- 
tion which was followed by disaggregation (fig. 2). 
3.3. Effect of antiaggregating substances on 
ALBa IgG-induced platelet aggregation 
(ALB6 IgG at 4 pug/ml) 
With aspirin up to 100 pg/ml) only a slight in- 
hibition was observed. No inhibition was observed 
with ticlopidin (up to 2.5 x 10m3 M). Total inhibi- 
tion was observed with chlorpromazin (100 
pg/ml), diltiazem (400 pg/ml), verapamil (400 
pg/ml), EDTA (12.5 PM) and PGEr (1.25 PM). 
The concentrations used were chosen after 
establishing controls with the usual aggregating 
drugs (ADP, collagen, thrombin). 
Buffer 
,Control 





Fig. 2. Effect of ALEa Fab fragments on platelet ag- 
gregation i duced by ionophore A 23 187. The inhibition 
is partial at 15 /IM A 23187 which induces a 
characteristic aggregation after preincubation for 5 min 
with the buffer control. The inhibition is total at 7.5 PM 
A 23187 but this concentration leads only to partial 
platelet aggregation in the control curve. 
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3.4. Immunojluorescence 
Platelets from 8 different donors were tested and 
a bright membrane fluorescence was observed in 
each case. The platelets of one patient with Ber- 
nard Soulier syndrome and one patient with type I 
thrombasthenia were also tested and the same 
fluorescence was observed. 
3.5 . [1Z51]Fibrinogen-binding to platelets in the 
presence of AL& Fab 
Without ALBe Fab, ADP-treated platelets 
bound 7% [rz51]fibrinogen. In the presence of 
ALBs Fab, the binding was reduced to 3.5%. In 
the absence of ADP and ALB6 Fab the non- 
specific binding was 1%. 
3.6. M, determination of the platelet component 
recognized by AL& 
The antigen defined by the monoclonal antibody 
ALB6 in platelets has an app. A4, of 24000. No 
other band appeared in the ALBa IgG- 
immunoadsorbed 12sI-labelled platelet extract run 
under reducing conditions (fig. 3). 
4. DISCUSSION 
The monoclonal antibody ALBa prepared 
against all cells recognizes a membrane protein of 
it4, 24000 (p 24). The epitope recognized by this 
antibody is widely distributed in the body tissues 
including membrane platelets. 
Affinity chromatography of ‘Z51-labelled NP 40 
membrane extracts followed by SDS-PAGE has 
shown that the molecule recognized by ALB6 on 
platelet membrane has the same i&value. 
Preliminary experiments using electrofocusing and 
immunoblotting indicate that the isoelectric point 
of the p 24 is identical in platelets and leukemic 
cells (~1% 7.6, not shown). In leukemic cells this 
molecule has been largely studied and it appears as 
a single polypeptide chain which is located outside 
the cell membrane and it does not form an intimate 
association with the lipid matrix [4]. Positive reac- 
tions in immunofluorescence using platelets from 
type I thrombasthenia and Bernard Soulier syn- 
drome indicate that the epitope is not on the major 
platelet membrane glycoproteins GP I, GP V : and 
the complex GP IIB-III A; therefore ALBa is dif- 
ferent from the antibodies AN 51 [9] and 6 Dl [lo] 
which recognize GP I as well as B 59.2 [l 11, which 
recognizes the complex GP II B-III A. 
Fig. 3. M, determination of the antigen recognized by 
ALE6 on platelets was performed using microcolumns of
immunoadsorbents linked to monoclonal antibodies 
followed by SDS-PAGE electrophoresis of the bound 
material. Platelets were previously labelled with “‘1 and 
extracted with NET-NP40 (see text): (a,d) 14C-labelled 
protein markers, in order of decreasing Mr 
values: myosin, phosphorylase b, BSA, ovalbumin (par- 
tially degraded), carbonic anhydrase, lactoglobulin A, 
cytochrome c; (b) eluate of the AL&j IgG microcolumn 
(antiCALLA gp 100 which is not expressed on 
platelets). Fluorography for r4C-labelled proteins and an 
intensifying screen for 1251-labellecl platelet extracts were 
combined to obtain this autoradiography. 
To analyze the possible role of the p 24 in the 
platelet membrane, the effect of ALBa was tested 
on platelet functions. As shown in these ex- 
periments the McAb ALB6 acts as an aggregating 
agent. This effect meets all necessary criteria for an 
aggregation : absence of lysis demonstrated by 
absence of LDH release, inhibition by various 
substances which could not inhibit an im- 
munological agglutination. ALB6 IgG-induced 
platelet aggregation occurred with normal platelets 
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and platelets from patients with Bernard Soulier 
syndrome, but no aggregation occurred with 
platelets from thrombasthenia type I and type II. 
The first point is the requirement of bivalence of 
AL&i for the induction of aggregation since the 
Fab fragments do not induce the effect. Moreover, 
the Fab fragments inhibit aggregation induced by 
ADP, collagent, thrombin, ALE6 IgG and 
ionophore A 23187, but do not inhibit ristocetin- 
induced agglutination. This indicates that the p 24 
in platelets is involved in aggregation of platelets 
induced by a variety of stimuli such as ADP, col- 
lagen, thrombin and A 23187. Therefore, it is 
assumed that the biological effect of this antibody 
infers a common metabolic requirement for all ag- 
gregation pathways. A direct blocking effect of the 
fibrinogen receptor, essential to platelet aggrega- 
tion, is not likely to be concerned since throm- 
basthenia type I platelets with < 1% GP II B-III 
A which bears the receptor for fibrinogen [11] are 
identically labelled by AL&. Thus the defect in 
fibrinogen-binding induced by pre-incubation of 
platelets with AI& Fab before adding ADP was 
due to an inhibitory effect on the mechanism 
which involves the exposure of the platelet 
fibrinogen binding site. On the other hand, EDTA 
and all anti-calcium drugs inhibit ALI& IgG- 
induced aggregation. These substances, like AL& 
Fab, have a relatively non-specific effect [12,13] 
since Ca2+ is involved crucially in the process of 
aggregation [14,15] and some of these drugs are 
known as calcium channel blockers [16,17] since 
the antibody does not penetrate into the platelet, 
AL&i platelet interaction could involve either a 
constituent of the putative calcium channel or a 
membrane protein which plays a role in the level of 
free cytoplasmic Ca2+ flux. It must be noted that 
it has been shown [18] that a M, 23000 protein 
regulates the calcium efflux from isolated mem- 
brane platelet vesicles; therefore, further studies 
will be undertaken to compare the p 24 and this 
phosphoprotein. 
In conclusion, the aggregating properties of this 
antibody could be of interest in two different 
fields : on the one hand by helping to understand 
some aspects of platelet aggregation; on the other 
hand the functional effect observed on platelets 
could lead to explanations for the restricted expres- 
sion and the role of this molecule, originally 
described as a differentiation antigen. 
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